SCHEMBL5217375

SCHEMBL5217375

CC(C)(CN)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
TAAR1 Q96RJ0 1/20 0.42
TSHR P16473 1/20 0.42
KAT2B Q92831 2/20 0.41
CTSD P07339 1/20 0.41
NPC1 O15118 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19222047 0.84 NPSR1 (0.53) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL29033626 0.82 NPSR1 (0.51) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL4372849 0.82 NPSR1 (0.55) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL23929022 0.81 NPSR1 (0.57) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL4008025 0.79 NPSR1 (0.56) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL9336413 0.79 NPSR1 (0.59) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL419987 0.79 NPSR1 (0.59) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL30486812 0.79 NPSR1 (0.59) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL28552981 0.77 NPSR1 (0.57) NPSR1HSD17B10ALDH1A1MEN1KMT2A
SCHEMBL318437 0.77 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869041-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2007-12-26 EP disclosed
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2006-10-19 US disclosed
WO-2006103559-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2006-10-05 WO disclosed
US-6492378-B1 Substituted isoquinoline derivatives and their use as anticonvulsivants SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-10 US disclosed
EP-1104404-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2001-06-06 EP disclosed
WO-2000009486-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSIVANTS SMITHKLINE BEECHAM P.L.C. (GB) 2000-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia PTGDR, GRIN2A, PTGDR2 NPSR1 752/4885HSD17B10 942/4885ALDH1A1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.